Tenaya Therapeutics Inc. (NASDAQ:TNYA) is one of the overlooked growth stocks to buy. On January 8, Morgan Stanley lowered the firm’s price target on Tenaya Therapeutics to $2 from$5 and kept an Overweight rating on the shares. In a sector outlook note, the firm predicted that the US small-to-mid cap biotech stocks will continue to outperform in 2026. This bullish view is driven by commercial-stage companies transitioning from capital consumers to producers and a looming patent cliff that is currently thr ...